摘要
目的:探讨高压氧治疗能否促进丹参和确炎舒松局部注射治疗口腔粘膜下纤维性变的治疗效果及其安全性。方法:设计随机临床试验,对随机分成3组的46名口腔粘膜下纤维性变患者进行单纯高压氧治疗、单纯注射丹参和确炎舒松治疗及联合两种治疗共8周。在治疗结束和治疗结束后12周进行最大开口度及口腔粘膜感觉的检查。结果:经过8周治疗,3组患者表现出不同的治疗效果,无明显不良反应。A组在治疗结束时和随访12周后最大开口度分别为(2.94±1.01)mm和(1.98±0.78)mm,B组分别为(3.89±0.67)mm和(3.18±0.66)mm,C组分别为(6.14±1.46)mm和(5.42±1.53)mm。A组在治疗结束时和随访12周后口腔粘膜感觉改善分别为(2.00±0.72)和(1.15±0.31),B组为(3.08±0.73)和(2.08±0.60),C组为(3.38±0.94)和(2.80±0.78)。结论:高压氧治疗能够促进丹参和确炎舒松局部注射治疗口腔粘膜下纤维性变的治疗效果且具有安全性。
Objective： To prove the safety and promotion effect of hyperbaric oxygenation treatment in oral submucous fibroisis patients with local injection with Danshen and triamcinolone acetonide. Methods： 46 patients were assigned into three groups randomly in the clinical trial. The patients in group A accepted hyperbaric oxygenation treatment twice a week for 8 weeks. The patients in group B accepted local injection with Danshen and triamcinolone acetonide for 8 weeks. The patients in group C accepted both treatment for 8 weeks. Results： The patients in three groups presented different curing effect without obvious side effect. At 8 weeks, the maximum mouth opening was （2.94±1.01）mm, （3.89±0.67）ram, and （6.14±1.46）mm in group A, B, and C, respectively. At 12 weeks after the finish of treatment, the maximum mouth opening was （2.94±1.01）mm and （1.98±0.78）mm, （3.18±0.66）ram and （5.42±1.53）ram in group A, B, and C, respectively. The amelioration degree of mouth sense was （1.15±0.31）, （2. 08±0.60）, and （2. 80±0.78） in group A, B, and C at 8 weeks, respectively. At 12 weeks after the finish of treatment, the amelioration degree of mouth sense was （2.00± 0.72）, （3.08 ± 0.73）, （3.38 ± 0.94） in group A, B, and C at 8 weeks, respectively. Conclusion： Hyperbaric oxygenation treatment could promote the curing effect of local injection with danshen and triamcinolone acetonide with good rate and safety.
出处
《口腔医学研究》
CAS
CSCD
北大核心
2015年第2期156-159,共4页
Journal of Oral Science Research
基金
郴州市第一人民医院新技术项目(项目号:CZYY2011-012)
关键词
高压氧
丹参
确炎舒松
口腔粘膜下纤维性变
Hyperbaric oxygenation Danshen Triamcinolone acetonide Oral submucous fibrosis
